INTERPACE BIOSCIENCES, INC. 8-K

What Happened

• Interpace Biosciences, Inc. (IDXG) announced its results of operations and financial condition for the fourth quarter and fiscal year ended December 31, 2025 in a press release dated March 30, 2026. The company filed Form 8‑K on April 1, 2026 to disclose that press release; the full text is included as Exhibit 99.1 to the filing.

Key Details

• The press release announcing Q4 and full‑year 2025 results is dated March 30, 2026 and is attached to the 8‑K as Exhibit 99.1.
• The reporting period covered is the fourth quarter and fiscal year ended December 31, 2025.
• The Form 8‑K was filed on April 1, 2026 (Accession No. 0001493152-26-014654).
• The filing also includes the Inline XBRL cover page file (Exhibit 104).

Why It Matters

• This 8‑K provides retail investors with the company’s latest quarterly and annual operating results and financial condition — information that can influence valuation and near‑term trading. Investors should read the attached press release (Exhibit 99.1) for revenue, profit/loss, cash position, and any management commentary, and compare those results with prior periods and guidance in other filings before making investment decisions.